Compare CRWS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRWS | RLYB |
|---|---|---|
| Founded | 1957 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 89.2M |
| IPO Year | 1994 | 2021 |
| Metric | CRWS | RLYB |
|---|---|---|
| Price | $2.50 | $16.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 83.0K | 7.3K |
| Earning Date | 02-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.49% | N/A |
| EPS Growth | ★ 118.89 | N/A |
| EPS | 0.17 | ★ 6.16 |
| Revenue | ★ $70,270,000.00 | $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.00 | ★ $2.70 |
| Revenue Growth | 6.51 | ★ 43.00 |
| 52 Week Low | $2.35 | $0.48 |
| 52 Week High | $3.14 | $17.57 |
| Indicator | CRWS | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 32.53 | 48.88 |
| Support Level | $2.45 | $16.49 |
| Resistance Level | $2.92 | $17.30 |
| Average True Range (ATR) | 0.08 | 0.38 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 18.97 | 37.97 |
Crown Crafts Inc operates in the infant and toddler products segment of the consumer products industry through its wholly-owned subsidiaries. The infant and toddler products segment consists of infant and toddler bedding, bibs, soft bath products, disposable products, and accessories. The company serves a diverse range of customers including mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs, and internet-based retailers. The company's brands include NoJo, Neat Solutions, Sassy, and Carousel. Its products are marketed under a variety of company-owned trademarks, under trademarks licensed from others, and as private-label goods.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.